generics
Some production halted at generics maker Aurobindo
U.S. inspectors found nine different quality control issues at an Aurobindo plant in India, causing the generic drug maker to halt manufacturing on some of its production lines. Aurobindo is one of the largest generic drug makers, and this news underscores the ongoing issue of drug shortage and quality from some suppliers.
"At this point in time, we don't foresee any material impact on the business," Aurobindo said in a filing with the Bombay Stock Exchange. But the site, which is in Telangana, India, manufactures more than 150 products, including essential injectables and eye drops for the U.S. market. The facility also makes about 30 products for sale by other companies, including Walgreens and McKesson. At least six products are on the FDA's shortages list, including dexamethasone sodium phosphate and methylprednisolone acetate injections.
Read more.
obesity
The safety profile of weight loss drugs
New drugs treating obesity have exploded in popularity, but questions remain over their safety profile in the longer term. Nature has published a very handy review of the safety profile of weight loss medicines — ranging from the newer GLP-1 medicines to older approaches like phentermine.
Drugs like semaglutide, liraglutide, tirzepatide, orlistat, and naltrexone combined with bupropion can have issues that range from headache and vomiting to acute kidney injury, the review shows. It finds that data supports using the gut-hormone receptor analogues to treat the obesity epidemic, but that continuous surveillance of side effects is critical moving forward — the data that cinched their approval "may have been insufficient to unveil all the safety issues," the paper says.
No comments